FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
Pochopień, M. T.; Cherney, D. Z. I.; Folkerts, K.; Lévy, Pierre; Millier, Aurélie; Morris, S.; Roy-Chaudhury, P.; Sullivan, S. D.; Mernagh, P. (2021), FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes, American Journal of Managed Care, 27, 20, p. S375-S382. 10.37765/ajmc.2021.88808
TypeArticle accepté pour publication ou publié
Journal nameAmerican Journal of Managed Care
MetadataShow full item record
Author(s)Pochopień, M. T.
Cherney, D. Z. I.
Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
Laboratoire d'Economie de Dauphine [LEDa]
Sullivan, S. D.
Abstract (EN)BACKGROUND : Chronic kidney disease (CKD) is a progressive and irreversible disease often associated with type 2 diabetes (T2D). CKD is associated with an elevated risk of cardiovascular (CV) events, increased mortality, and diminished quality of life. Finerenone is a new treatment for patients with CKD and T2D that delays CKD progression and reduces CV complications. OBJECTIVE : To describe the approach and structure of a costeffectiveness model for finerenone for patients with CKD and T2D and compare it with existing economic models in CKD. METHODS : A de novo cost-effectiveness model (FINE-CKD model), reflective of FIDELIO-DKD results, was developed for finerenone. The FINE-CKD model was designed and implemented in accordance with published guidance on modeling and was developed with input from economic and clinical experts. The final model approach was evaluated against existing modeling structures in CKD identified through a systematic literature review. RESULTS AND CONCLUSIONS : The FINE-CKD model structure follows recommended modeling guidelines and has been designed in accordance with the best practices of modeling in CKD, while also incorporating important features of the FIDELIO-DKD design and results. The approach is consistent with the published literature, ensuring transparency and minimizing uncertainty that can arise from unnecessary complexity. The FINE-CKD model allows for reliable assessment of benefits and costs related to the use of finerenone in patients with CKD and T2D, and it is a reliable assessment of cost-effectiveness.
Subjects / KeywordsChronic disease; Quality of life; Health economics
Showing items related by title and author.
Potential Budgetary Impact of Large Scale Screening of Small Fiber Neuropathy in the Follow-Up of Patients with Type 2 Diabetes in France Lévy, Pierre; Bordier, Lyse; Calvet, Jean-Henri; Le Hérissé, Gaëlle; Bauduceau, Bernard (2015) Article accepté pour publication ou publié
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation Briere, Jean-Baptiste; Wu, Olivia; Bowrin, Kevin; Millier, Aurélie; Toumi, Mondher; Taieb, Vanessa; Lévy, Pierre; Coleman, Craig I. (2019) Article accepté pour publication ou publié
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation Coleman, Craig I.; Briere, Jean-Baptiste; Fauchier, Laurent; Fauchier, Laurent; Lévy, Pierre; Bowrin, Kevin; Toumi, Mondher; Millier, Aurélie; Taieb, Vanessa; Wu, Olivia (2019) Article accepté pour publication ou publié
Bowrin, Kevin; Briere, Jean-Baptiste; Lévy, Pierre; Toumi, Mondher; Millier, Aurélie (2020-06) Article accepté pour publication ou publié
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France Chouaid, Christos; Bensimon, Lionel; Clay, Emilie; Millier, Aurélie; Levy-Bachelot, Laurie; Huang, Min; Lévy, Pierre (2019) Article accepté pour publication ou publié